🇨🇭·3h agoIndustry
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Publisher
R
Roche Newsroom
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- July 24, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Aspen Pharmacare/2h ago
Strengthening partnerships, visibility and sustainable progress in the CDMO space
Nippon Shinyaku News/3h ago
「第97回 都市対抗野球大会」組み合わせ決定 日本新薬は鹿嶋市代表「日本製鉄鹿島」と対戦
Merck & Co. (MSD) News/3h ago
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Chugai Pharmaceutical News/7h ago